** Shares of drug developer Forte Biosciences FBRX.O rise 132.4% to $13.77
** Company says private placement of its shares, worth $53 mln, oversubscribed
** Funds to support development of company's experimental drug, FB102, to treat autoimmune diseases - FBRX
** Received support from new and existing investors, including OrbiMed, Janus Henderson Investors and Tybourne Capital Management - CEO Paul Wagner
** Despite session's gains, stock down 34.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。